22 November 2021 : Clinical Research
Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation
Bangying Zhang1ABCDEF, Xinpei Chen1BCDE, Xiaofeng Mu1BDE, Enzhao Liu1AB, Tong Liu1BE, Gang Xu1BC, Qiankun Bao1CDE, Guangping Li1AFG*DOI: 10.12659/MSM.932813
Med Sci Monit 2021; 27:e932813
Table 1 Baseline characteristics of the study participants.
| Control group n=61 | Atrial fibrillation n=60 | P value | |
|---|---|---|---|
| Age, year | 68.51±6.55 | 70.93±8.53 | 0.082 |
| Male gender, n (%) | 31 (50.8%) | 27 (45.0%) | 0.522 |
| Hypertension, n (%) | 46 (75.4%) | 43 (71.7%) | 0.641 |
| Diabetes mellitus, n (%) | 17 (27.9%) | 17 (28.3%) | 0.955 |
| Previous stroke, n (%) | 9 (14.8%) | 10 (16.7%) | 0.772 |
| Coronary heart disease, n (%) | 34 (55.7%) | 35 (58.3%) | 0.773 |
| eGFR, mL/min | 86.49±15.08 | 91.12±20.23 | 0.156 |
| eGFR – estimated glomerular filtration rate. Data are means±standard deviation (SD). | |||